News und Analysen
Convatec Group PLC: Director/ PDMR Shareholding
Convatec Group PLC: Total Voting Rights
Ergomed (ERGO): Two key management changes
Silence Therapeutics Reports Third Quarter 2022 Results
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through
Silence Therapeutics to Present at Jefferies London Healthcare Conference
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through
Silence Therapeutics Presents New Analysis from SLN360 Phase 1 Single Dose Study in High Lipoprotein(a) at the American Heart Association (AHA) 2022 Annual Meeting
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through
Convatec Group PLC:
Ergomed (ERGO): Poised for a strong FY22
Convatec Group PLC: Director/ PDMR Shareholding
Silence Therapeutics Announces Preliminary Single Dose Results from SLN124 Phase 1 Study in Patients with Thalassemia
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the
Silence Therapeutics to Participate in Fireside Chat at Chardan Genetic Medicines Conference
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the
Hardman & Co Research on Tissue Regenix (TRX): Operating leverage
Convatec Group PLC: Scrip Dividend - Total Issued Shares
Convatec Group PLC: Results of 2022 AGM – Update Statement
Convatec Group PLC: Scrip Dividend – Calculation Price
Silence Therapeutics to Participate in September Investment Conferences
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the
Silence Therapeutics Announces FDA Fast Track Designation for SLN124, a Novel Investigational siRNA Therapy for the Treatment of Polycythemia Vera
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the
Form 8.3 - Maitland Institutional Services Limited: Re Diurnal Group plc
Convatec Group PLC: Director/PDMR Shareholding
Silence Therapeutics Announces Pricing of Underwritten Offering
Silence Therapeutics plc (Nasdaq: SLN) (“Silence”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of
Hardman & Co Research: Q&A on Tissue Regenix Group plc: Significantly undervalued which should correct
Ergomed (ERGO): Sustained growth momentum in H122
Hardman & Co Research : Tissue Regenix (TRX): Strong 1H’22 sales suggest upside potential
GSK prepares US for 2022-23 flu season with over 50 million influenza vaccine doses
GSK plc (LSE/NYSE: GSK) today announced it has started shipping doses of its quadrivalent influenza vaccines to US healthcare providers and pharmacies in preparation for the 2022-23 season. This
GSK Selects Target the Future Grant Recipient in Innovation Challenge Supporting Multiple Myeloma Community
GSK plc today announced the first recipient of the Target the Future Think Tank Challenge £70,000 (equivalent to approximately $100,000) grant to the HealthTree Foundation, a non-profit